UCN2 and polymyositis: This ranged from a median probability of 0.78 (IQR, 0.19) for individuals with anti-Jo-1 and anti-SRP (polymyositis; P = 8.4 × 10−151) to 0.81 (IQR, 0.20) for individuals with lupus anti-coagulant, anti-cardiolipin, and anti-β2 glycoprotein (antiphospholipid syndrome; P = 9.8 × 10−242).